2025-07-22 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc (RXRX), incorporating the provided data.

**Report on Recursion Pharmaceuticals Inc (RXRX)**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop drugs.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (RXRX):** -40.78%
*   **Cumulative Return (VOO):** 36.17%
*   **Divergence:**
    *   Max: 35.8
    *   Min: -88.1
    *   Current: -81.8
    *   Relative Divergence: 5.1

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period. The relative divergence of 5.1 indicates that the current divergence is near its historical worst, suggesting the stock is significantly lagging behind its benchmark.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -1.0%  | -0.1  | 4.3    |
| 2022-2024  | 0.0%   | 73.6%  | -25.0% | 0.1   | 2.9    |
| 2023-2025  | 11.0%  | 73.6%  | -38.0% | 0.1   | 2.8    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows fluctuating performance. The most recent period (2023-2025) shows the highest CAGR, but this needs to be considered alongside other factors.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha is negative across all periods, suggesting that RXRX has underperformed relative to its benchmark, even after adjusting for risk. The negative alpha is becoming more pronounced over time.
*   **Beta:** Beta is very low, hovering around zero, indicating RXRX is not strongly correlated with the overall market. This could suggest that RXRX's performance is driven by factors specific to the company or its industry, rather than broad market movements.
*   **Cap(B):** Market capitalization has decreased, reflecting the stock's poor performance.

**2. Recent Price Action**

*   **Current Price:** $6.40
*   **Previous Close:** $5.84
*   **Change:** 9.59%
*   **5-day Moving Average:** $5.67
*   **20-day Moving Average:** $5.34
*   **60-day Moving Average:** $4.99

**Analysis:** The stock experienced a significant jump in the last trading session (+9.59%). The current price is above all moving averages, suggesting a short-term upward trend. However, it's crucial to assess if this is sustainable or a temporary bounce.

**3. Market Risk Indicators & Expected Return**

*   **MRI:** 0.3383 (Low Risk)
*   **RSI:** 72.26 (Overbought)
*   **PPO:** 1.43
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence (20-day):** 3.2 (+) - Short-term Increase
*   **Expected Return:** -480.9% (Long-Term)

**Analysis:**

*   The MRI indicates low market risk.
*   The RSI is in overbought territory, suggesting the stock may be due for a pullback.
*   The positive change in the relative divergence indicates a short-term upward trend.
*   The Hybrid Signal recommends a partial buy, but with caution, given the MRI.
*   The extremely negative expected return suggests that, based on current data, long-term investment may lead to significant underperformance compared to the S&P 500.
*   The significant price change (+9.59%) indicates a potential volatile event (news, earnings-related).

**4. Recent News & Significant Events**

*   **[2025-07-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-19]:** Analyst discussions on performance, industry trends, and global economic factors.
*   **[2025-07-20]:** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-07-18]:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news points to significant events impacting RXRX, including volatility, analyst discussions, and potential business/regulatory changes. Investors should monitor news releases and company announcements closely.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-05-05 | -0.50 | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.40 | 0.01 B$  |
| 2024-05-09 | -0.39 | 0.01 B$  |
| 2025-05-05 | -0.39 | 0.01 B$  |

**Analysis:** RXRX consistently reports negative EPS, and revenue is relatively low. This indicates that the company is not yet profitable. The earnings situation needs to be carefully evaluated in the context of the company's cash runway and future growth prospects.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |
| 2024-03-31 | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-03-31 | $0.93B  | -21.68% |
| 2024-12-31 | $1.03B  | -17.29% |
| 2024-09-30 | $0.52B  | -18.27% |
| 2024-06-30 | $0.58B  | -16.69% |
| 2024-03-31 | $0.40B  | -22.78% |

**Analysis:**

*   **Revenue:** Revenue is inconsistent.
*   **Profit Margin:** Profit margins are unstable, with some quarters showing positive margins and others showing significant losses.
*   **Equity:** Equity fluctuates, but is generally decreasing.
*   **ROE:** ROE is consistently negative, indicating poor profitability.

**7. Overall Summary**

RXRX has significantly underperformed the S&P 500, exhibits high volatility and negative profitability. Recent news suggests major events are unfolding. While there's been a recent price jump and the MRI indicates low risk, the RSI is overbought and the expected return is substantially negative. The company is losing money, with unstable profit margins and negative ROE.

**Recommendation:**

Based on the data, caution is warranted. The company is struggling financially and its stock performance has been poor. Investors should carefully monitor news and company announcements, considering the significant risks associated with this stock. Further due diligence is needed.
